New hepatitis b drug enters first human tests
NCT ID NCT07024641
First seen Oct 31, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This early-stage trial is testing a new drug called GIGA-2339 in 48 people with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo by IV infusion, and researchers will monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Grifols Investigate Site
RECRUITINGConcord, New South Wales, 2139, Australia
Contact
-
Grifols Investigative Site
RECRUITINGPeachtree Corners, Georgia, 30071, United States
Contact
-
Grifols Investigative Site
RECRUITINGIowa City, Iowa, 52242, United States
Contact
-
Grifols Investigative Site
RECRUITINGLenexa, Kansas, 66219, United States
Contact
-
Grifols Investigative site
RECRUITINGChandler, Arizona, 85225, United States
Contact
-
Grifols Investigative site
RECRUITINGHuntington Beach, California, 92647, United States
Contact
-
Grifols Investigative site
RECRUITINGLake Forest, California, 92630, United States
Contact
-
Grifols Investigative site
RECRUITINGLong Beach, California, 90805, United States
Contact
-
Grifols Investigative site
RECRUITINGOakland, California, 94605, United States
Contact
-
Grifols Investigative site
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
-
Grifols Investigative site
RECRUITINGSan Antonio, Texas, 78215, United States
Contact
-
Grifols Investigative site
RECRUITINGWebster, Texas, 77598, United States
Contact
-
Grifols Investigative site
RECRUITINGRichmond, Virginia, 23284, United States
Contact
-
Grifols Investigative site
RECRUITINGFortitude Valley, Queensland, 4006, Australia
Contact
-
Grifols Investigative site
RECRUITINGHong Kong, Hong Kong Island, Hong Kong
Contact
-
Grifols Investigative site
RECRUITINGShatin, New Territories, Hong Kong
Contact
-
Grifols Investigative site
RECRUITINGSeogu, Busan, South Korea
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GIGA-2339 (a drug given by intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option to help control chronic hepatitis B virus infection.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs do not advance.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.